Johnson & Johnson (NYSE:JNJ) Position Terminated by Ironwood Investment Management LLC


Ironwood Investment Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 58.9% in Q1, according to the company’s latest Form 13F filing with the SEC. The firm held 2,506 shares of the company’s stock after selling 3,587 shares in the quarter. Ironwood Investment Management LLC’s shares in Johnson & Johnson were valued at $444,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their shares. Family CFO Inc took a new position at Johnson & Johnson in the fourth quarter worth approximately $26,000. RE Dickinson Investment Advisors LLC increased its stake in Johnson & Johnson’s shares by 163.3% in Q1. RE Dickinson Investment Advisors LLC now owns 158 shares of the company, valued at $28,000, after purchasing an additional 98 shares last quarter. Professional Financial Advisors LLC increased its stake in Johnson & Johnson stock by 47.9% in Q1. Professional Financial Advisors LLC now owns 210 shares of the company, valued at $37,000, after purchasing an additional 68 shares last quarter. Joseph P. Lucia & Associates LLC purchased a new $38,000 stake in Johnson & Johnson stock in Q1. Finally, Advocacy Wealth Management Services LLC increased its holdings in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company, valued at $41,000, after purchasing an additional 67 shares last quarter. 68.78% of the stocks are owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened Friday at $169.31. The company’s fifty-day moving average is $173.43 and its two-hundred-day moving average is $174.56. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company’s debt/equity ratio is 0.37, current ratio is 1.42 and quick ratio is 1.17. The firm has a market capitalization of $445.15 billion, a price-to-earnings ratio of 24.64, a P/L/N ratio of 3.17, and a beta of 0.59.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, July 19. The company reported earnings per share for the quarter of $2.59, beating the consensus estimate of $2.57 by $0.02. The business generated $24.02 billion in revenue for the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a 19.21% net margin and 36.14% return on equity. The company’s revenue increased 3.0% year-on-year. In the same quarter last year, the company earned $2.48 per share. Equity research analysts estimate Johnson & Johnson will post EPS of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend payable on Tuesday, September 6. Record investors will receive a dividend of $1.13 on Tuesday, August 23. The old dividend distribution date of this dividend is Monday, August 22. This represents an annual dividend of $4.52 and a return of 2.67%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Insiders Place Their Bets

In other news, CAO Robert J. Decker sold 8,462 shares on Thursday, May 26. Shares were sold at an average price of $180.00, with a total value of $1,523,160.00. Upon completion of the transaction, the chief accounting officer currently owns 15,473 shares in the company worth approximately $2,785,140. The sale was disclosed in a filing with the SEC available at this link. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction Friday, June 10. The stock sold for an average price of $173.00, with a total value of $6,920,000.00. Following the sale, the vice president now directly owns 71,311 shares in the company worth approximately $12,336,803. The transaction was disclosed in a filing with the SEC available on the SEC website. In addition, CAO Robert J. Decker sold 8,462 shares of the firm in a transaction that took place on Thursday, May 26. The stock sold for an average price of $180.00, with a total value of $1,523,160.00. Following the transaction, the chief accounting officer owned 15,473 shares of the company, worth approximately $2,785,140. Description of this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Discusses

JNJ has been the subject of several analyst reports recently. UBS Group lowered its price target at Johnson & Johnson from $185.00 to $180.00 in a research note Thursday, July 21. Wells Fargo & Company raised its target price on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report Wednesday, July 13. Morgan Stanley raised its price target for Johnson & Johnson stock from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report Friday, July 8. StockNews.com upgraded Johnson & Johnson’s shares from a “buy” rating to a “strong buy” rating in a report released Tuesday, May 17. Most recently, Daiwa Capital Markets covered Johnson & Johnson shares in a report released Wednesday, June 22. They gave the stock an “outstanding performance” rating. Four stock research analysts rated the stock with a holding rating, five gave it a buy rating, and one gave the company’s stock a strong buy rating. According to data from MarketBeat, the company currently has an average “Medium Buy” rating and an average target price of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells a variety of healthcare products worldwide. The company’s Consumer Healthcare segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; Skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Quarterly Corporate Ownership for Johnson & Johnson (NYSE:JNJ)



Get News and Ratings for Johnson & Johnson Daily – Enter your email address below to receive a brief daily summary of the latest news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.